We are live on ! Find out more
MIM

MetLife Investment Management Portfolio holdings

AUM $19.6B
1-Year Est. Return 32.64%
This Fund
S&P 500
This Quarter Est. Return
+10.56%
1 Year Est. Return
+32.64%
3 Year Est. Return
+107.14%
5 Year Est. Return
+140.16%
10 Year Est. Return
AUM
$12.2B
AUM Growth
+$1.03B
Cap. Flow
+$49.2M
Cap. Flow %
0.4%
Top 10 Hldgs %
25.44%
Holding
2,628
New
63
Increased
565
Reduced
814
Closed
130

Sector Composition

Rank Sector Weight
1 Technology 22.34%
2 Healthcare 12.24%
3 Financials 12%
4 Consumer Discretionary 11.44%
5 Industrials 8.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SMSI icon
2451
Smith Micro Software
SMSI
$17M
$81.2K ﹤0.01%
+413
New +$90.3K
KALV
2452
DELISTED
KalVista Pharmaceuticals
KALV
$81.1K ﹤0.01%
6,130
FRBA icon
2453
First Bank
FRBA
$469M
$81K ﹤0.01%
+5,582
New +$82.9K
RIGL icon
2454
Rigel Pharmaceuticals
RIGL
$782M
$78.4K ﹤0.01%
2,958
-3,199
-52% -$96.5K
OMER icon
2455
Omeros
OMER
$992M
$77.8K ﹤0.01%
12,105
-11,054
-48% -$80.2K
ALDX icon
2456
Aldeyra Therapeutics
ALDX
$91.7M
$74.9K ﹤0.01%
18,715
+9,298
+99% +$70.9K
EGIO
2457
DELISTED
Edgio, Inc. Common Stock
EGIO
$74.4K ﹤0.01%
542
-581
-52% -$69.1K
WSR
2458
DELISTED
Whitestone REIT
WSR
$73.2K ﹤0.01%
7,228
-8,250
-53% -$80.4K
RBBN icon
2459
Ribbon Communications
RBBN
$372M
$72K ﹤0.01%
11,903
-13,072
-52% -$77.5K
AKBA icon
2460
Akebia Therapeutics
AKBA
$248M
$69.6K ﹤0.01%
30,797
-32,929
-52% -$89.8K
PASG icon
2461
Passage Bio
PASG
$14.8M
$68.1K ﹤0.01%
537
DSKE
2462
DELISTED
Daseke, Inc. Common Stock
DSKE
$63.5K ﹤0.01%
6,324
-8,121
-56% -$79.8K
TACO
2463
DELISTED
Del Taco Restaurants, Inc. Common Stock
TACO
$59.9K ﹤0.01%
4,814
-6,279
-57% -$60.6K
IVVD icon
2464
Invivyd
IVVD
$216M
$56.2K ﹤0.01%
7,740
GAN
2465
DELISTED
GAN Ltd
GAN
$49.5K ﹤0.01%
5,389
-9,181
-63% -$112K
PGEN icon
2466
Precigen
PGEN
$2.45B
$49.3K ﹤0.01%
13,296
-21,265
-62% -$91.5K
CTOS icon
2467
Custom Truck One Source
CTOS
$2.46B
$46.5K ﹤0.01%
5,816
-10,676
-65% -$92K
EZPW icon
2468
Ezcorp Inc
EZPW
$1.78B
$46.3K ﹤0.01%
6,282
-11,443
-65% -$86.9K
PRVB
2469
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$41.7K ﹤0.01%
7,413
-13,272
-64% -$84.3K
IMVT icon
2470
Immunovant
IMVT
$8.8B
$41K ﹤0.01%
4,807
-10,202
-68% -$84.2K
ABUS icon
2471
Arbutus Biopharma
ABUS
$907M
$38.8K ﹤0.01%
9,980
-20,062
-67% -$77.9K
TCS
2472
DELISTED
THE CONTAINER STORE GROUP, INC.
TCS
$38.3K ﹤0.01%
256
-517
-67% -$87.3K
COGT icon
2473
Cogent Biosciences
COGT
$6.76B
$36.6K ﹤0.01%
4,267
-9,755
-70% -$84.8K
LAB icon
2474
Standard BioTools
LAB
$312M
$36.5K ﹤0.01%
9,309
-20,592
-69% -$96.4K
TRUE
2475
DELISTED
TrueCar
TRUE
$33.1K ﹤0.01%
9,722
-24,237
-71% -$92.2K

Similar funds

MetLife Investment Management's Q4 2021 Portfolio in Review

As of Q4 2021, MetLife Investment Management held 2,628 positions worth $12.2B, up 9.2% from $11.2B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

MetLife Investment Management's Q4 2021 filing shows 63 new, 565 increased, 814 reduced and 130 closed positions. Its largest new stake was iShares iBoxx $ Investment Grade Corporate Bond ETF: 2,855,000 shares worth $378M. The largest sale was Enterprise Products Partners, an estimated $31.9M.

By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 21% a quarter earlier, followed by Healthcare and Financials.

  • MetLife Investment Management's largest Q4 2021 buy was iShares iBoxx $ Investment Grade Corporate Bond ETF: 2,855,000 shares worth $378M.
  • MetLife Investment Management added most to iShares Russell 2000 ETF in Q4 2021, an estimated $14.1M increase.
  • MetLife Investment Management's biggest Q4 2021 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $31.2M.
  • MetLife Investment Management fully exited Enterprise Products Partners in Q4 2021, selling an estimated $31.9M.
  • MetLife Investment Management's ten largest holdings make up 25% of its $12.2B portfolio in Q4 2021.
  • MetLife Investment Management opened 63 new positions and closed 130 in Q4 2021.
  • MetLife Investment Management's portfolio value rose 9.2% quarter-over-quarter to $12.2B.

Based on MetLife Investment Management's 13F filing for Q4 2021, filed 15 Feb 2022.